KUROME THERAPEUTICS
Kurome Therapeutics is a preclinical stage company focused on subverting cancer's ability to evade therapy. The company is developing therapies that target cancer cells that have co-opted immune signaling pathways to avoid destruction by traditional therapeutic agents and subvert adaptive resistance mechanisms.
KUROME THERAPEUTICS
Social Links:
Industry:
Biotechnology Health Care Therapeutics
Founded:
2019-01-01
Address:
Cincinnati, Ohio, United States
Country:
United States
Website Url:
http://www.kurometherapeutics.com
Total Employee:
1+
Status:
Active
Contact:
513-445-3852
Email Addresses:
[email protected]
Total Funding:
15 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SSL By Default Google Font API Google Analytics Google Tag Manager Google Universal Analytics Global Site Tag Fastly Fastly Hosted
Similar Organizations
Acrivon Therapeutics
Acrivon Therapeutics is a precision oncology therapeutics company specializing in drug development through early clinical treatment success.
Context Therapeutics
Context Therapeutics is a clinical-stage biopharmaceutical company.
Edgewise Therapeutics
Edgewise Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization.
Current Advisors List
Current Employees Featured
Founder
Investors List
Affinity Asset Advisors
Affinity Asset Advisors investment in Series A - Kurome Therapeutics
Queen City Angels
Queen City Angels investment in Series A - Kurome Therapeutics
CincyTech
CincyTech investment in Series A - Kurome Therapeutics
Medicxi
Medicxi investment in Series A - Kurome Therapeutics
CincyTech
CincyTech investment in Seed Round - Kurome Therapeutics
Official Site Inspections
http://www.kurometherapeutics.com
- Host name: 67.227.188.112
- IP address: 67.227.188.112
- Location: Lansing United States
- Latitude: 42.7348
- Longitude: -84.6245
- Metro Code: 551
- Timezone: America/Detroit
- Postal: 48917
More informations about "Kurome Therapeutics" on Search Engine
Kurome Therapeutics - Crunchbase Company Profile
Kurome Therapeutics is a preclinical stage company focused on subverting cancer's ability to evade therapy. Cincinnati, Ohio, United States. 11-50. Series A. Private. …See details»
Kurome Therapeutics Company Profile 2024: Valuation, …
The company's therapies target the dysregulated immune signaling pathways that become over-activated in cancer cells and contribute to cancer cell survival, thereby enabling …See details»
Kurome Therapeutics, Inc. | LinkedIn
Headquarters. Cincinnati, Ohio. Type. Privately Held. Founded. 2019. Specialties. oncology, therapeutics, drug development, diagnostics, biomarkers, IRAK inhibitors, FLT3 …See details»
CORRECTING and REPLACING Kurome Therapeutics …
Feb 15, 2024 Kurome Therapeutics Inc. is pleased to announce that the U.S. Food and Drug Administration (FDA) has cleared the IND for KME-0584, allowing the company to …See details»
Kurome Therapeutics Closes $15 Million Series A …
Jun 10, 2021 CINCINNATI-- ( BUSINESS WIRE )-- Kurome Therapeutics, a preclinical stage company dedicated to developing novel therapies that target adaptive resistance …See details»
Kurome Therapeutics Announces FDA Clearance of …
Feb 15, 2024 CINCINNATI-- (BUSINESS WIRE)--Kurome Therapeutics Inc. is pleased to announce that the U.S. Food and Drug Administration (FDA) has cleared the IND for …See details»
Kurome Therapeutics: Rosenbaum’s Leadership Journey to …
Kurome Therapeutics is a preclinical stage company developing an unprecedented, targeted approach for treating hematological cancers.See details»
Kurome Therapeutics Announces FDA Clearance of IND …
Feb 16, 2024 Cincinnati, Ohio – Kurome Therapeutics Inc. is pleased to announce that the U.S. Food and Drug Administration (FDA) has cleared the IND for KME-0584, …See details»
Kurome Therapeutics - Updates, News, Events, Signals & Triggers
Mar 1, 2024 Organization. Kurome Therapeutics. Connect to CRM. Summary Financials People Technology Signals & News Similar Companies. Growth Insight Details. …See details»
Kurome Therapeutics Announces FDA Clearance of ... - BioSpace
Feb 15, 2024 CINCINNATI-- ( BUSINESS WIRE )-- Kurome Therapeutics Inc. is pleased to announce that the U.S. Food and Drug Administration (FDA) has cleared the IND for …See details»
Kurome raises $15M to overcome adaptive resistance in leukemia
Jun 10, 2021 Kurome Therapeutics has raised $15 million to treat acute myeloid leukemia (AML) by targeting adaptive resistance mechanisms. Medicxi and Affinity Asset Advisors …See details»
Kurome Therapeutics - Funding, Financials, Valuation & Investors
Kurome Therapeutics has raised a total of. $15M. in funding over 2 rounds. Their latest funding was raised on Jun 10, 2021 from a Series A round. Kurome Therapeutics is …See details»
CORRECTING and REPLACING Kurome Therapeutics …
Feb 15, 2024 Kurome ® Therapeutics is a privately held clinical stage biotechnology company developing novel therapies that target dysregulated immune signalling in cancer.See details»
FDA Approves Kurome's Clinical Trials for AML and Advanced …
Feb 22, 2024 Kurome Therapeutics Inc. is excited to report that the IND for KME-0584 has been approved by the U.S. Food and Drug Administration. This approval grants the …See details»
Kurome Therapeutics | CipherBio
Kurome Therapeutics is developing therapies that target cancer cells that have co-opted immune signaling pathways in order to avoid destruction by traditional therapeutic …See details»
Press Release Archives - Kurome Therapeutics
Kurome Therapeutics Announces FDA Clearance of Investigational New Drug (IND) Application for KME-0584 for the Treatment of Acute Myeloid Leukemia (AML) and High …See details»
Kurome Therapeutics - Contacts, Employees, Board Members, …
Kurome Therapeutics. Connect to CRM. Summary Financials People Technology Signals & News Similar Companies. Highlights. Employee Profiles 2. Number of Board Member …See details»
Therapeutics Development Center at Harrington Discovery …
Jan Rosenbaum, PhD is President, CEO and CSO of Kurome. She is a drug development professional, chief scientific officer, and innovator with more than 25 years of …See details»
News Articles Archives - Kurome Therapeutics
Kurome Therapeutics Announces FDA Clearance of Investigational New Drug (IND) Application for KME-0584 for the Treatment of Acute Myeloid Leukemia (AML) and High …See details»